NCT05614115View on ClinicalTrials.gov

Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

March 21, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
End-stage Kidney DiseaseKidney Disease, ChronicDialysisDiabeticNon-diabeticKidney DysfunctionKidney FailureHemodialysis
Interventions
DRUG

Empagliflozin

is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.

OTHER

Placebo

Placebo comparator

Trial Locations (1)

84132

University of Utah, Salt Lake City

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Utah

OTHER